Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 9/2016

01-09-2016 | Original Article

Gene expression profile analysis in response to α1,2-fucosyl transferase (FUT1) gene transfection in epithelial ovarian carcinoma cells

Authors: Song Gao, Liancheng Zhu, Huilin Feng, Zhenhua Hu, Shan Jin, Zuofei Song, Dawo Liu, Juanjuan Liu, Yingying Hao, Xiao Li, Bei Lin

Published in: Tumor Biology | Issue 9/2016

Login to get access

Abstract

The aim of this study was to identify differentially expressed genes (DEGs) in response to α1,2-fucosyl transferase (FUT1) gene transfection in epithelial ovarian cancer cells. Human whole-genome oligonucleotide microarrays were used to determine whether gene expression profile may differentiate the epithelial ovarian cell line Caov-3 transfected with FUT1 from the empty plasmid-transfected cells. Quantitative real-time PCR and immunohistochemical staining validated the microarray results. Gene expression profile identified 215 DEGs according to the selection criteria, in which 122 genes were upregulated and 93 genes were downregulated. Gene Ontology (GO) and canonical pathway enrichment analysis were applied, and we found that these DEGs are involved in BioCarta mammalian target of rapamycin (mTOR) pathway, BioCarta eukaryotic translation initiation factor 4 (EIF4) pathway, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways in cancer. Interaction network analysis predicted genes participating in the regulatory connection. Highly differential expression of TRIM46, PCF11, BCL6, PTEN, and FUT1 genes was validated by quantitative real-time PCR in two cell line samples. Finally, BCL6 and Lewis Y antigen were validated at the protein level by immunohistochemistry in 103 paraffin-embedded ovarian cancer tissues. The identification of genes in response to FUT1 may provide a theoretical basis for the investigations of the molecular mechanism of ovarian cancer.
Appendix
Available only for authorised users
Literature
1.
Pliarchopoulou K, Pectasides D. Epithelial ovarian cancer: focus on targeted therapy. Crit Rev Oncol Hematol. 2011;79:17–23.CrossRefPubMed
2.
Iwamori M, Tanaka K, Kubushiro K, Lin B, Kiguchi K, Ishiwata I, Tsukazaki K, Nozawa S. Alterations in the glycolipid composition and cellular properties of ovarian carcinoma-derived RMG-1 cells on transfection of the alpha1,2-fucosyltransferase gene. Cancer Sci. 2005;96:26–30.CrossRefPubMed
3.
4.
5.
Yan LM, Lin B, Zhu LC, Hao YY, Qi Y, Wang CZ, Gao S, Liu SC, Zhang SL, Iwamori M. Enhancement of the adhesive and spreading potentials of ovarian carcinoma RMG-1 cells due to increased expression of integrin alpha5beta1 with the Lewis Y-structure on transfection of the alpha1,2-fucosyltransferase gene. Biochimie. 2010;92:852–7.CrossRefPubMed
6.
Zhang F, Liu J, Lin B, Liu Q, Zhao Y, Zhu L, Hao Y, Zhang S, Iwamori M. Increase in docetaxel-resistance of ovarian carcinoma-derived RMG-1 cells with enhanced expression of Lewis Y antigen. Int J Mol Sci. 2011;12:7323–34.CrossRefPubMedPubMedCentral
7.
Gao N, Liu J, Liu D, Hao Y, Yan L, Ma Y, Zhuang H, Hu Z, Gao J, Yang Z, Shi H, Lin B. c-Jun transcriptionally regulates alpha 1, 2-fucosyltransferase 1 (FUT1) in ovarian cancer. Biochimie. 2014;107(Pt B):286–92.CrossRefPubMed
8.
Hu Z, Gao S, Gao J, Hou R, Liu C, Liu J, Li B, Liu D, Zhang S, Lin B. Elevated levels of Lewis y and integrin alpha5beta1 correlate with chemotherapeutic drug resistance in epithelial ovarian carcinoma. Int J Mol Sci. 2012;13:15588–600.CrossRefPubMedPubMedCentral
9.
Gao J, Hu Z, Liu D, Liu J, Liu C, Hou R, Gao S, Zhang D, Zhang S, Lin B. Expression of Lewis y antigen and integrin alphav, beta3 in ovarian cancer and their relationship with chemotherapeutic drug resistance. J Exp Clin Cancer Res CR. 2013;32:36.CrossRefPubMed
10.
Hu Z, Gao J, Zhang D, Liu Q, Yan L, Gao L, Liu J, Liu D, Zhang S, Lin B. High expression of Lewis y antigen and CD44 is correlated with resistance to chemotherapy in epithelial ovarian cancers. PLoS One. 2013;8:e57250.CrossRefPubMedPubMedCentral
11.
Tan M, Zhu L, Zhuang H, Hao Y, Gao S, Liu S, Liu Q, Liu D, Liu J, Lin B. Lewis Y antigen modified CD47 is an independent risk factor for poor prognosis and promotes early ovarian cancer metastasis. Am J Cancer Res. 2015;5:2777–87.PubMedPubMedCentral
12.
Gao J, Hu Z, Liu J, Liu D, Wang Y, Cai M, Zhang D, Tan M, Lin B. Expression of CD147 and Lewis y antigen in ovarian cancer and their relationship to drug resistance. Med Oncol. 2014;31:920.CrossRefPubMed
13.
Zhang D, Gao J, Zhu L, Hu Z, Hou R, Liu S, Tan M, Liu J, Lin B. Chemoresistance is associated with MUC1 and Lewis y antigen expression in ovarian epithelial cancers. Int J Mol Sci. 2013;14:11024–33.CrossRefPubMedPubMedCentral
14.
Wang H, Zhu L, Gao J, Hu Z, Lin B. Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells. Oncol Rep. 2015;33:403–12.PubMed
15.
Zhu L, Gao J, Hu Z, Schwab C, Zhuang H, Tan M, Yan L, Liu J, Zhang D, Lin B. Membranous expressions of Lewis y and CAM-DR-related markers are independent factors of chemotherapy resistance and poor prognosis in epithelial ovarian cancer. Am J Cancer Res. 2015;5:830–43.PubMedPubMedCentral
16.
Zhuang H, Tan M, Liu J, Li X, Gao J, Hu Z, Deng L, Zhu L, Lin B. The expression of annexin II and Lewis y antigen in ovarian epithelial tumors and the correlation between them. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2015;36:2343–9.CrossRef
17.
Wang ST, Liu JJ, Wang CZ, Lin B, Hao YY, Wang YF, Gao S, Qi Y, Zhang SL, Iwamori M. Expression and correlation of Lewis y antigen and TGF-beta1 in ovarian epithelial carcinoma. Oncol Rep. 2012;27:1065–71.PubMed
18.
Zhuang H, Hu Z, Tan M, Zhu L, Liu J, Liu D, Yan L, Lin B. Overexpression of Lewis y antigen promotes human epididymis protein 4-mediated invasion and metastasis of ovarian cancer cells. Biochimie. 2014;105:91–8.CrossRefPubMed
19.
Zhu L, Zhuang H, Wang H, Tan M, Schwab CL, Deng L, Gao J, Hao Y, Li X, Gao S, Liu J, Lin B. Overexpression of HE4 (human epididymis protein 4) enhances proliferation, invasion and metastasis of ovarian cancer. Oncotarget. 2016;7:729–44.PubMed
20.
Liu J, Lin B, Hao Y, Qi Y, Zhu L, Li F, Liu D, Cong J, Zhang S, Iwamori M. Lewis y antigen promotes the proliferation of ovarian carcinoma-derived RMG-I cells through the PI3K/Akt signaling pathway. J Exp Clin Cancer Res. 2009;28:154.CrossRefPubMedPubMedCentral
21.
Liu D, Liu J, Wang C, Lin B, Liu Q, Hao Y, Zhang S, Iwamori M. The stimulation of IGF-1R expression by Lewis(y) antigen provides a powerful development mechanism of epithelial ovarian carcinoma. Int J Mol Sci. 2011;12:6781–95.CrossRefPubMedPubMedCentral
22.
Yan L, Wang C, Lin B, Liu J, Liu D, Hou R, Wang Y, Gao L, Zhang S, Iwamori M. Lewis y enhances CAM-DR in ovarian cancer cells by activating the FAK signaling pathway and upregulating Bcl-2/Bcl-XL expression. Biochimie. 2015;113:17–25.CrossRefPubMed
23.
Li FF, Liu JJ, Liu DW, Lin B, Hao YY, Cong JP, Zhu LC, Gao S, Zhang SL, Iwamori M. Lewis Y regulates signaling molecules of the transforming growth factor beta pathway in ovarian carcinoma-derived RMG-I cells. Int J Oncol. 2012;40:1196–202.PubMed
24.
Zhuang H, Gao J, Hu Z, Liu J, Liu D, Lin B. Co-expression of Lewis y antigen with human epididymis protein 4 in ovarian epithelial carcinoma. PLoS One. 2013;8:e68994.CrossRefPubMedPubMedCentral
25.
Diaz-Montana JJ, Diaz-Diaz N. Development and use of the Cytoscape app GFD-Net for measuring semantic dissimilarity of gene networks. F1000 Res. 2014;3:142.
26.
Smaletz O, Diz MD, do Carmo CC, Sabbaga J, Cunha-Junior GF, Azevedo SJ, Maluf FC, Barrios CH, Costa RL, Fontana AG, Madrigal V, Wainstein AJ, Yeda FP, Alves VA, Moro AM, Blasbalg R, Scott AM, Hoffman EW. A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma. Gynecol Oncol. 2015;138:272–7.CrossRefPubMed
27.
Zhuang H, Tan M, Liu J, Hu Z, Liu D, Gao J, Zhu L, Lin B. Human epididymis protein 4 in association with annexin II promotes invasion and metastasis of ovarian cancer cells. Mol Cancer. 2014;13:243.CrossRefPubMedPubMedCentral
28.
Liu D, Liu J, Lin B, Liu S, Hou R, Hao Y, Liu Q, Zhang S, Iwamori M. Lewis y regulate cell cycle related factors in ovarian carcinoma cell RMG-I in vitro via ERK and Akt signaling pathways. Int J Mol Sci. 2012;13:828–39.CrossRefPubMedPubMedCentral
29.
Manocha GD, Mishra R, Sharma N, Kumawat KL, Basu A, Singh SK. Regulatory role of TRIM21 in the type-I interferon pathway in Japanese encephalitis virus-infected human microglial cells. J Neuroinflammation. 2014;11:24.CrossRefPubMedPubMedCentral
30.
Raheja R, Liu Y, Hukkelhoven E, Yeh N, Koff A. The ability of TRIM3 to induce growth arrest depends on ring-dependent E3 ligase activity. Biochem J. 2014;458:537–45.CrossRefPubMedPubMedCentral
31.
Bell JL, Malyukova A, Kavallaris M, Marshall GM, Cheung BB. TRIM16 inhibits neuroblastoma cell proliferation through cell cycle regulation and dynamic nuclear localization. Cell Cycle. 2013;12:889–98.CrossRefPubMedPubMedCentral
32.
Chen L, Chen DT, Kurtyka C, Rawal B, Fulp WJ, Haura EB, Cress WD. Tripartite motif containing 28 (Trim28) can regulate cell proliferation by bridging HDAC1/E2F interactions. J Biol Chem. 2012;287:40106–18.CrossRefPubMedPubMedCentral
33.
Zhou Z, Ji Z, Wang Y, Li J, Cao H, Zhu HH, Gao WQ. TRIM59 is up-regulated in gastric tumors, promoting ubiquitination and degradation of p53. Gastroenterology. 2014;147:1043–54.CrossRefPubMed
34.
Zhan W, Han T, Zhang C, Xie C, Gan M, Deng K, Fu M, Wang JB. TRIM59 promotes the proliferation and migration of non-small cell lung cancer cells by upregulating cell cycle related proteins. PLoS One. 2015;10:e0142596.CrossRefPubMedPubMedCentral
35.
Yaguchi H, Okumura F, Takahashi H, Kano T, Kameda H, Uchigashima M, Tanaka S, Watanabe M, Sasaki H, Hatakeyama S. TRIM67 protein negatively regulates ras activity through degradation of 80K-H and induces neuritogenesis. J Biol Chem. 2012;287:12050–9.CrossRefPubMedPubMedCentral
36.
Feng Z, Lin B, Xu Y, Zhu L, Liu J, Gao J. Efficacy analysis of combining three comparative-omics profilings to screen candidate biological macromolecules. Mol Biol Rep. 2013;40:1861–6.CrossRefPubMed
37.
Kannan K, Kordestani GK, Galagoda A, Coarfa C, Yen L. Aberrant MUC1-TRIM46-KRTCAP2 chimeric RNAs in high-grade serous ovarian carcinoma. Cancers (Basel). 2015;7:2083–93.CrossRef
38.
Jardin F, Ruminy P, Bastard C, Tilly H. The BCL6 proto-oncogene: a leading role during germinal center development and lymphomagenesis. Pathol Biol (Paris). 2007;55:73–83.CrossRef
39.
Bentebibel SE, Schmitt N, Banchereau J, Ueno H. Human tonsil B-cell lymphoma 6 (BCL6)-expressing CD4+ T-cell subset specialized for B-cell help outside germinal centers. Proc Natl Acad Sci U S A. 2011;108:E488–97.CrossRefPubMedPubMedCentral
40.
Wang W, Hu S, Lu X, Young KH, Medeiros LJ. Triple-hit B-cell lymphoma with MYC, BCL2, AND BCL6 translocations/rearrangements: clinicopathologic features of 11 cases. Am J Surg Pathol. 2015;39:1132–9.CrossRefPubMed
41.
Wagner SD, Ahearne M, Ko Ferrigno P. The role of BCL6 in lymphomas and routes to therapy. Br J Haematol. 2011;152:3–12.CrossRefPubMed
42.
Jarosova M, Kriegova E, Schneiderova P, Fillerova R, Prochazka V, Mikesova M, Flodr P, Indrak K, Papajik T. A novel non-immunoglobulin (non-Ig)/BCL6 translocation in diffuse large B-cell lymphoma involving chromosome 10q11.21 loci and review on clinical consequences of BCL6 rearrangements. Pathol Oncol Res. 2015;22:233–43.CrossRefPubMed
43.
Hirata Y, Ogasawara N, Sasaki M, Mizushima T, Shimura T, Mizoshita T, Mori Y, Kubota E, Wada T, Tanida S, Kataoka H, Kamiya T, Higashiyama S, Joh T. BCL6 degradation caused by the interaction with the C-terminus of pro-HB-EGF induces cyclin D2 expression in gastric cancers. Br J Cancer. 2009;100:1320–9.CrossRefPubMedPubMedCentral
44.
Liang PI, Li CF, Chen LT, Sun DP, Chen TJ, Hsing CH, Hsu HP, Lin CY. BCL6 overexpression is associated with decreased p19 ARF expression and confers an independent prognosticator in gallbladder carcinoma. Tumour Biol. 2014;35:1417–26.CrossRefPubMed
45.
Wu Q, Liu X, Yan H, He YH, Ye S, Cheng XW, Zhu GL, Wu WY, Wang XN, Kong XJ, Xu XC, Lobie PE, Zhu T, Wu ZS. B-cell lymphoma 6 protein stimulates oncogenicity of human breast cancer cells. BMC Cancer. 2014;14:418.CrossRefPubMedPubMedCentral
46.
Sena P, Mariani F, Benincasa M, De Leon MP, Di Gregorio C, Mancini S, Cavani F, Smargiassi A, Palumbo C, Roncucci L. Morphological and quantitative analysis of BCL6 expression in human colorectal carcinogenesis. Oncol Rep. 2014;31:103–10.PubMed
47.
Worsham MJ, Lu M, Chen KM, Stephen JK, Havard S, Schweitzer VP. Malignant and nonmalignant gene signatures in squamous head and neck cancer. J Oncol. 2012;2012:752860.CrossRefPubMedPubMedCentral
48.
Yu JM, Sun W, Hua F, Xie J, Lin H, Zhou DD, Hu ZW. BCL6 induces EMT by promoting the ZEB1-mediated transcription repression of E-cadherin in breast cancer cells. Cancer Lett. 2015;365:190–200.CrossRefPubMed
49.
Shan W, Li J, Bai Y, Lu X. miR-339-5p inhibits migration and invasion in ovarian cancer cell lines by targeting NACC1 and BCL6. Tumour Biol. 2015;37:5203–11.CrossRefPubMed
50.
Wu ZS, Wu Q, Wang CQ, Wang XN, Wang Y, Zhao JJ, Mao SS, Zhang GH, Zhang N, Xu XC. MiR-339-5p inhibits breast cancer cell migration and invasion in vitro and may be a potential biomarker for breast cancer prognosis. BMC Cancer. 2010;10:542.CrossRefPubMedPubMedCentral
51.
Wang YQ, Xu MD, Weng WW, Wei P, Yang YS, Du X. BCL6 is a negative prognostic factor and exhibits pro-oncogenic activity in ovarian cancer. Am J Cancer Res. 2015;5:255–66.PubMed
52.
53.
Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, Warren A, Scott H, Madhu B, Sharma N, Bon H, Zecchini V, Smith DM, Denicola GM, Mathews N, Osborne M, Hadfield J, Macarthur S, Adryan B, Lyons SK, Brindle KM, Griffiths J, Gleave ME, Rennie PS, Neal DE, Mills IG. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 2011;30:2719–33.CrossRefPubMedPubMedCentral
54.
Lin F, Marcelo KL, Rajapakshe K, Coarfa C, Dean A, Wilganowski N, Robinson H, Sevick E, Bissig KD, Goldie LC, Means AR, York B. The camKK2/camKIV relay is an essential regulator of hepatic cancer. Hepatology. 2015;62:505–20.CrossRefPubMedPubMedCentral
55.
Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12:21–35.CrossRefPubMed
Metadata
Title
Gene expression profile analysis in response to α1,2-fucosyl transferase (FUT1) gene transfection in epithelial ovarian carcinoma cells
Authors
Song Gao
Liancheng Zhu
Huilin Feng
Zhenhua Hu
Shan Jin
Zuofei Song
Dawo Liu
Juanjuan Liu
Yingying Hao
Xiao Li
Bei Lin
Publication date
01-09-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5080-4

Other articles of this Issue 9/2016

Tumor Biology 9/2016 Go to the issue

Original Article

Synergistic increase in efficacy of a combination of 2-deoxy-d-glucose and cisplatin in normoxia and hypoxia: switch from autophagy to apoptosis

Original Article

Feedback mechanisms between M2 macrophages and Th17 cells in colorectal cancer patients

Original Article

Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer

Review

Role of interleukin-6 in cancer progression and therapeutic resistance

Original Article

Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia

Review

Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits